Anika Therapeutics, Inc. (ANIK) NASDAQ

14.57

-0.03(-0.21%)

Updated at June 09 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Stephen D. Griffin	President, Principal Financial Officer, CEO & Director	818,148	1986
Ian W. McLeod	Senior VP, Chief Accounting Officer & Treasurer	489,601	1966
David Colleran	Executive Vice President, General Counsel & Corporate Secretary	724,581	1972
Cheryl Renee Blanchard	Executive Chair	1.41M	1964
Lisa Funiciello	VP & Chief Human Resources Officer	0	N/A
Matthew Hall	Executive Director of Corporate Development & Investor Relations	0	N/A
Ben Joseph	Vice President of Commercial & Corporate Development	0	N/A
James Chase	Senior Vice President of International Sales & Marketing	0	N/A
Mark Namaroff	Vice President of Investor Relations, ESG & Corporate Communications	0	1963
Mira Leiwant	Senior Vice President of Regulatory, Quality & Clinical Affairs	0	N/A

Name

Title

Pay

Year Born

Stephen D. Griffin

President, Principal Financial Officer, CEO & Director

818,148

1986

Ian W. McLeod

Senior VP, Chief Accounting Officer & Treasurer

489,601

1966

David Colleran

Executive Vice President, General Counsel & Corporate Secretary

724,581

1972

Cheryl Renee Blanchard

Executive Chair

1.41M

1964

Lisa Funiciello

VP & Chief Human Resources Officer

N/A

Matthew Hall

Executive Director of Corporate Development & Investor Relations

N/A

Ben Joseph

Vice President of Commercial & Corporate Development

N/A

James Chase

Senior Vice President of International Sales & Marketing

N/A

Mark Namaroff

Vice President of Investor Relations, ESG & Corporate Communications

1963

Mira Leiwant

Senior Vice President of Regulatory, Quality & Clinical Affairs

N/A

Description

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.